reports
scPharmaceuticals Inc. Reports Second Quarter 2025 Financial Results a...
scPharmaceuticals Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update Generated net FUROSCIX® revenue of $16 million in the second quarter of 2025; up 99% over Q2 2024 Doses shipped to patients increased 45% over Q1 2025 and 117% over Q2 2024 Launch of FUROSCIX in chronic kidney disease Autoinjector remains on track for sNDA submission in Q3 2025; designed to reduce treatment time from five hours to less than ten seconds Cash and cash equivalents of $40.8 million as of June 30, 2025 Investor conference call and webcast today, Thursday, August 7th, at 4:30pm ...
scPharmaceuticals to Announce Second Quarter 2025 Financial Results Af...
scPharmaceuticals to Announce Second Quarter 2025 Financial Results After the Market Close on August 7, 2025 Management to host conference call and webcast, after-market on August 7, 2025, at 4:30 p.m. ET BURLINGTON, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Thursday, August 7, 2025, to discuss the financial results for the ...
- Dave Nicoski
- Ross LaDuke
RCKY ROCKY BRANDS
PZZA PAPA JOHN'S INTERNATIONAL INC.
PLAY DAVE & BUSTER'S ENTERTAINMENT INC.
MU MICRON TECHNOLOGY INC.
MSA MSA SAFETY INC.
MPC MARATHON PETROLEUM CORPORATION
MCHP MICROCHIP TECHNOLOGY INCORPORATED
KOP KOPPERS HOLDINGS INC.
GPC GENUINE PARTS COMPANY
DLTR DOLLAR TREE INC.
DG DOLLAR GENERAL CORPORATION
CVGW CALAVO GROWERS INC.
BEN FRANKLIN RESOURCES INC.
AAP ADVANCE AUTO PARTS INC.
MEG. MEG ENERGY CORP.
FSLR FIRST SOLAR INC.
KALU KAISER ALUMINUM CORPORATION
PVH PVH CORP.
NHC NATIONAL HEALTHCARE CORP.
ELF E.L.F. BEAUTY INC.
DK DELEK US HOLDINGS INC
SCPH SCPHARMACEUTICALS INC
MTW MANITOWOC COMPANY INC.
TTEC TTEC HOLDINGS INC.
ADNT ADIENT PLC
ULBI ULTRALIFE
ELAN ELANCO ANIMAL HEALTH INC.
OCGN OCUGEN INC
ITOS ITEOS THERAPEUTICS
ETWO E2OPEN PARENT HOLDINGS INC (A)
PAX PATRIA INVESTMENTS
VAL VALARIS LTD
DINO HOLLYFRONTIER CORP
NE NOBLE CORP (NEW)
ADCT ADC THERAPEUTICS SA
SVV SAVERS VALUE VILLAGE INC
GUTS FRACTYL HEALTH INC
LRCX LAM RESEARCH CORPORATION
scPharmaceuticals Inc. Reports First Quarter 2025 Financial Results an...
scPharmaceuticals Inc. Reports First Quarter 2025 Financial Results and Provides Business Update Generated net FUROSCIX® revenue of $11.8 million in the first quarter of 2025 Formally launched FUROSCIX in second approved indication, Chronic Kidney Disease, in April 2025 Autoinjector on track for sNDA submission in Q3 2025; designed to reduce treatment time from five hours to less than ten seconds Cash and cash equivalents of $57.5 million as of March 31, 2025 Investor conference call and webcast today, Wednesday, May 14th, at 4:30pm ET BURLINGTON, Mass., May 14, 2025 (GLOBE NEWSWIRE)...
scPharmaceuticals to Announce First Quarter 2025 Financial Results Aft...
scPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 2025 Management to host conference call and webcast, after-market on May 14, 2025, at 4:30 p.m. ET BURLINGTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, May 14, 2025, to discuss the financial results for the first q...
scPharmaceuticals Announces Participation in Three Upcoming Investor C...
scPharmaceuticals Announces Participation in Three Upcoming Investor Conferences BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that John Tucker, President and Chief Executive Officer, will participate in the following upcoming investor conferences: The Citizens Life Sciences Conference: Presentation on Wednesday, May 7 at 9:30 a.m. ET.Craig-Hallum 22nd Annual Institutional Investor Conference: We...
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Finan...
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update scPharmaceuticals generated fourth quarter 2024 net FUROSCIX® revenue of $12.2 million, and full year 2024 revenue of $36.3 million Cash and cash equivalents of $75.7 million as of December 31, 2024 U.S. Food and Drug Administration (FDA) approved the FUROSCIX expanded label indication to include the treatment of edema due to fluid overload in patients with chronic kidney disease scPharmaceuticals to host investor conference call and webcast today, Wednesday, March 19th,...
scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financ...
scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025 Management to host conference call and webcast, after-market on March 19, 2025, at 4:30 p.m. ET BURLINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, March 19, 2025, to discuss the financial results for ...
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Appl...
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease FDA approves scPharmaceuticals’ supplemental New Drug Application to expand the FUROSCIX indication to include the treatment of edema in adult patients with chronic kidney disease, including nephrotic syndrome FUROSCIX is expected to be available for chronic kidney disease patients in April 2025 BURLINGTON, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), ...
scPharmaceuticals Announces Participation in Two Upcoming Investor Con...
scPharmaceuticals Announces Participation in Two Upcoming Investor Conferences BURLINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that John Tucker, President and Chief Executive Officer, will present at the following upcoming investor conferences: 45th Annual TD Cowen Healthcare Conference: Fireside chat on Wednesday, March 5 at 11:10AM ET.Leerink Partners 2025 Global Healthcare Conference: Corporate pre...
scPharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare...
scPharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference BURLINGTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that John Tucker, President & Chief Executive Officer, will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12 at 2:40PM ET. A webcast of the presentation can be accessed or under “News & Events” in the Invest...
scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Fu...
scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results Preliminary unaudited fourth quarter 2024 net revenue expected to be approximately $12 million to $12.3 million, representing 99% growth over Q4 2023 at the mid-point of the range Fourth quarter 2024 Gross-to-net (GTN) discount expected to be in the range of 18% to 19% Preliminary unaudited full year 2024 net revenue expected to be approximately $36.2 million to $36.5 million, compared to $13.6 million for full year 2023 BURLINGTON, Mass., Jan. 10, 2025 (GLOBE N...
scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results an...
scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update Generated 3Q 2024 net FUROSCIX® revenue of $10.0 million, up 164% from Q3 2023 Received approval of label expansion to include New York Heart Association (NYHA) Class IV Patients Announced positive pharmacokinetic/pharmacodynamic (PK/PD) data on Autoinjector program Completed $125 million transformative financing in a combination of debt and equity that is anticipated to fund the Company through expected profitability Company to host investor conference call and webcast today, Wednesday, N...
scPharmaceuticals to Announce Third Quarter 2024 Financial Results on ...
scPharmaceuticals to Announce Third Quarter 2024 Financial Results on Wednesday, November 13, 2024 Management to host conference call and webcast, after-market on November 13, 2024, at 4:30 p.m. ET BURLINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, November 13, 2024, to discuss the financial results for the thi...
- Gary Brode
scPharmaceuticals to Host Key Opinion Leader (KOL) Webinar on October ...
scPharmaceuticals to Host Key Opinion Leader (KOL) Webinar on October 22, 2024 Webinar to focus on a nephrologist’s perspective on the use of FUROSCIX for fluid overload in heart failure and potential use in chronic kidney disease BURLINGTON, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that it will host a KOL webinar focused on a nephrologis...
- Gary Brode
scPharmaceuticals to Present at the H.C. Wainwright 26th Annual Global...
scPharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference BURLINGTON, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference on Wednesday, September 11 at 10:00AM ET. Mr. Tucker will also ...
- Jonathan Moreland
- Jonathan Moreland
NCR NCR CORPORATION
TTSH TILE SHOP HOLDINGS INC.
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
PCRX PACIRA BIOSCIENCES INC.
ORRF ORRSTOWN FINANCIAL SERVICES INC.
OEC ORION ENGINEERED CARBONS SA
FTAI FORTRESS TRANSPORTATION AND INFRASTRUCTURE INVESTORS LLC
FLDM FLUIDIGM
CRK COMSTOCK RESOURCES INC.
APEI AMERICAN PUBLIC EDUCATION
CLOV CLOVER PAKISTAN LTD.
YUMC YUM CHINA HOLDINGS INC.
GBDC GOLUB CAPITAL BDC INC.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
APPN APPIAN
SCPH SCPHARMACEUTICALS INC
EYE NATIONAL VISION HOLDINGS
LILA LIBERTY LATIN AMERICA A
HHS HARTE-HANKS INC.
MGTX MEIRAGTX HOLDINGS PLC
HMNF HMN FINANCIAL INC.
ELAN ELANCO ANIMAL HEALTH INC.
LYFT LYFT
GRX INC.
NVST THE GABELLI HEALTHCARE & WELLNESSRX TRUST
XAIR ENVISTA HOLDINGS
GRWG BEYOND AIR
PGEN GROWGENERATION
ALTG PRECIGEN INC
ONEW ALTA EQUIPMENT GROUP INC.
TLS ONEWATER MARINE
FTCI TELOS
RPHM FTC SOLAR
VMEO INC.
TMCI RENEO PHARMACEUTICALS
TSE INC.
QSI VIMEO INC
PFHC TREACE MED CONCEPTS INC
RXO_w TRINSEO PLC
WRBY QUANTUM-SI INC
GRNT PROFRAC HLDG CORP
MBC_w RXO INC
FCCND WARBY PARKER INC
ET GRANITE RIDGE RESOURCES INC
GT MASTERBRAND INC
MIO SPECTRAL CAPITAL CORP
FIP ENERGY TRANSFER LP
GOODYEAR TIRE & RUBBER CO.
PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
FTAI INFRASTRUCTURE INC
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.